|Awarded On||November 19, 2015|
|Title||Engineered AXL Decoy Receptor for Treatment of AML & Solid Tumors|
|Program||Product Development Research|
|Award Mechanism||New Company Product Development Award|
|Institution/Organization||Aravive Biologics, Inc.|
|Principal Investigator/Program Director||Amato Giaccia|
|Cancer Sites||Leukemia, Ovary, Pancreas|
Ruga Corporation is a late preclinical stage pharmaceutical company developing Ruga-S6, an engineered decoy soluble AXL receptor, for targeted therapy against acute myeloid lymphoma (AML) and certain solid tumor indications including ovarian, pancreatic, and breast cancer.
AML is a hematologic cancer affecting both pediatric and adult patients. While the pediatric population is small (~800), over 18,000 adults are diagnosed in the US annually, with the majority of these patients over 65. Based on 1996-2002 SEER statistics, the 5-year survival rate for adults older than 65 diagnosed with AML was a mere 4.3%. In the past 20 years, there has been little improvement in overall survival for AML...